相似文献
1
Value-Based Care in Lung Cancer.
Oncologist. 2016 Aug;21(8):903-6. doi: 10.1634/theoncologist.2016-0116. Epub 2016 Jun 2.
2
Lung cancer cure, care, and cost: let the data be your guide.
J Clin Oncol. 1997 Sep;15(9):3027-9. doi: 10.1200/JCO.1997.15.9.3027.
3
[Merits of multidisciplinary treatment in lung cancer].
Nihon Rinsho. 2002 May;60 Suppl 5:433-7.
4
Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens.
Lung Cancer. 2015 Nov;90(2):274-80. doi: 10.1016/j.lungcan.2015.09.005. Epub 2015 Sep 10.
5
[Informed consent, QOL and cost benefit in the treatment of lung cancer].
Nihon Rinsho. 2000 May;58(5):1153-7.
6
Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
J Geriatr Oncol. 2015 Jul;6(4):324-31. doi: 10.1016/j.jgo.2015.05.002. Epub 2015 Jun 17.
7
[How to take into account the cost effectiveness parameters in the management of bronchial carcinoma?].
Rev Mal Respir. 2006 Sep;23(4 Pt 2):10S17-10S20.
8
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
JAMA Oncol. 2015 May;1(2):196-202. doi: 10.1001/jamaoncol.2015.0203.
9
[Medical-economic evaluation of bronchial cancer].
Rev Mal Respir. 1999 Jan;16 Suppl 3:S38-9.
10
Living and dying: up close and personal.
J Palliat Med. 2010 Jul;13(7):897-8. doi: 10.1089/jpm.2010.0029.
引用本文的文献
1
Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients.
Healthcare (Basel). 2023 Jan 18;11(3):293. doi: 10.3390/healthcare11030293.
2
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis.
Ther Adv Med Oncol. 2019 Dec 30;11:1758835919891652. doi: 10.1177/1758835919891652. eCollection 2019.
3
This is a call to oncologists for action.
Clin Transl Oncol. 2018 Dec;20(12):1493-1501. doi: 10.1007/s12094-018-1887-3. Epub 2018 May 23.
4
Early Steps in the Value of Cancer Care-Many Paths Remain Unexplored.
Oncologist. 2018 Apr;23(4):391-392. doi: 10.1634/theoncologist.2017-0611. Epub 2018 Feb 7.
5
Value: The Next Frontier in Cancer Care.
Oncologist. 2016 Jun;21(6):651-3. doi: 10.1634/theoncologist.2016-0174. Epub 2016 May 25.
本文引用的文献
1
Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
J Natl Cancer Inst. 2016 Feb 22;108(7). doi: 10.1093/jnci/djv429. Print 2016 Jul.
2
The patient-centered medical home in oncology: from concept to reality.
Am Soc Clin Oncol Educ Book. 2015:e82-9. doi: 10.14694/EdBook_AM.2015.35.e82.
3
Beyond "second-line" in non-small cell lung cancer: therapy and supportive care.
Am Soc Clin Oncol Educ Book. 2015:e414-8. doi: 10.14694/EdBook_AM.2015.35.e414.
4
Non-Small Cell Lung Cancer, Version 6.2015.
J Natl Compr Canc Netw. 2015 May;13(5):515-24. doi: 10.6004/jnccn.2015.0071.
5
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1225-36. doi: 10.1001/jamaoto.2014.1570.
6
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.
7
Shared decision making to improve care and reduce costs.
N Engl J Med. 2013 Jan 3;368(1):6-8. doi: 10.1056/NEJMp1209500.
8
Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers.
J Oncol Pract. 2012 May;8(3 Suppl):e38s-43s. doi: 10.1200/JOP.2012.000564.
9
Value-based purchasing--national programs to move from volume to value.
N Engl J Med. 2012 Jul 26;367(4):292-5. doi: 10.1056/NEJMp1204939.
10
Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs.
Health Aff (Millwood). 2012 Apr;31(4):780-5. doi: 10.1377/hlthaff.2012.0002.
Zotero 插件